Etanercept - TNF inhibitor for the treatment of inflammatory autoimmune diseases
Etanercept is a TNF inhibitor for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriasis. Find out more about its effects, use, risks and special features.
Regular tips about health Regular tips about healthWissenswertes über "Etanercept"
Etanercept is a TNF inhibitor for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriasis. Find out more about its effects, use, risks and special features.
Etanercept is a biotechnologically produced fusion protein, which is used as a so-called TNF inhibitor in inflammatory rheumatic diseases. It acts specifically against tumour necrosis factor alpha (TNF-α) - a key inflammatory mediator in the immune system.
Etanercept consists of the extracellular domain of the human TNF receptor type II, which is coupled to the Fc fragment of a human IgG1 antibody. This creates a stable, soluble protein that binds circulating TNF-α and thus blocks its pro-inflammatory effect.
Application areas
Etanercept is authorised in the EU and Germany for the following indications:
-
Rheumatoid arthritis (usually in combination with methotrexate)
-
Juvenile idiopathic arthritis
-
Morbus Bechterew (ankylosing spondylitis)
-
Non-radiographic axial spondyloarthritis
It is primarily used when conventional basic therapy (e.g. methotrexate) is not sufficiently effective.
Application and dosage
Etanercept is injected subcutaneously (under the skin) - typically once or twice a week. The dosage depends on age, body weight and disease. Trade names include Enbrel® or Benepali®.
.Side effects and risks
The most common side effects include:
Less common, but to be taken seriously:
-
Severe infections (e.g. tuberculosis, fungal infections)
-
Reactivation of latent infections
-
Autoimmune reactions, neurological side effects
-
Rare cases of malignancies (e.g. lymphomas)
Therefore, screening for tuberculosis, hepatitis B/C and other chronic infections is required before starting therapy.
Special features and differentiation
Compared to other TNF inhibitors such as adalimumab or adalimumab, Infliximab, etanercept is a soluble TNF receptor fusion, not an antibody. As a result, its efficacy profile differs slightly, for example in certain tissue diseases or susceptibility to infection.
Etanercept has a relatively short half-life, which allows better controllability of the therapy.
Importance in biologics therapy
Etanercept is one of the very first approved biologics and has revolutionised the treatment of chronic inflammatory diseases. It is exemplary for the use of recombinant fusion proteins in immunomodulation and is constantly being developed further - for example through biosimilars and new formulations.
Literature references:
-
Smolen, J. S. et al. (2017). ""Treating rheumatoid arthritis to target: recommendations of an international task force."" Annals of the Rheumatic Diseases
-
European Medicines Agency (EMA): ""Etanercept - Product Information.""
-
Tracey, D. et al. (2008). ""Tumour necrosis factor antagonist mechanisms of action: a comprehensive review."" Pharmacology & Therapeutics
Best-selling products
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryAstrocytoma
Balneotherapy
Radial Head Fracture
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Cologne list
Calorie content
Related search terms: Etanercept